Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
Conditions
Keywords
NSCLC, HCC, HNSCC, Resectable
Brief summary
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe and what side effects they cause; and other details about how they function in the body. One of the treatments that will be combined cemiplimab is another experimental drug called fianlimab. In this form, cemiplimab and fianlimab will each individually be called "study drug" or "study drugs" when combined. Cemiplimab (also known as REGN2810) and fianlimab (also known as REGN3767) are both a type of drug called a monoclonal antibody. Antibodies are proteins naturally found in your blood that fight infections. A monoclonal antibody is a special kind of antibody that is manufactured as a medication to target specific proteins in the body that may be involved in your cancer. * Cemiplimab is a drug that blocks the programmed death receptor 1 (PD-1), a cell receptor on immune cells * Fianlimab is a drug that blocks the action of a protein called lymphocyte activation gene (LAG)-33 (LAG-3)
Interventions
DRUGcemiplimab
Administered intravenous (IV)
DRUGPlatinum Doublet
Administered intravenous (IV)
DRUGfianlimab
Administered IV
Sponsors
Regeneron Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
Cohorts B and C are not randomized
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Patient must have a known diagnosis of NSCLC, HCC, or HNSCC as defined in the protocol * Patient must be willing and able to provide blood samples at the indicated time points * Patient must be willing and able to have excisional or core needle biopsies of tumor prior to initiation of cemiplimab as defined in the protocol * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Patient is determined to be a surgical candidate for resection of their tumor * Adequate organ and bone marrow function as defined in the protocol Key
Exclusion criteria
* Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor * Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery * Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer) * Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy * Patients with metastatic disease for whom the intent of surgery would not be curative * Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator * Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment * Has active autoimmune disease that has required systemic treatment in the past 1 year * Has a known, additional malignancy that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy. * Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent * History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment. * Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol * NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime. * NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions. Note: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major pathologic response (MPR) at time of surgery for the NSCLC cohorts | At time of surgery | Cohorts A1, A2, A3 |
| Significant tumor necrosis (STN) at time of surgery is the primary endpoint for the HCC cohorts | At time of surgery | Cohort B, B2, B3 |
| Major treatment effect (MTE) at time of surgery is the primary endpoint for the HNSCC cohort | At time of surgery | Cohort C |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Delay to surgery | Surgery >28 days following the end of the cycle of last dose of cemiplimab | Defined as surgery \>28 days following the end of the second cycle of cohort specific neoadjuvant therapy |
| Event-free survival (EFS) | Up to 60 months following surgery | Defined as the time from the first study treatment to the date of disease progression that precluded definitive surgery, or recurrence of tumor after successful surgery, or death from any cause. |
| Disease-free survival (DFS) | Up to 60 months following surgery | Defined as the time from date of surgery until recurrence of tumor or death from any cause after successful surgery and recovery |
| Overall response rate (ORR) | Up to 60 months following surgery | Defined as the percent of patients with a complete response (CR) or partial response (PR) documented by the Investigator per RECIST 1.1. as described in the protocol |
| Overall survival (OS) | Up to 60 months following surgery | Defined as the time from the first study treatment and date of death for any reason |
| OS rate | 12 months | — |
| Incidence of treatment emergent adverse events (TEAEs) | Up to 60 months following surgery | Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0) |
| Incidence of imAEs | Up to 60 months following surgery | Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0) |
| Incidence of SAEs | Up to 60 months following surgery | Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0) |
| Incidence of deaths | Up to 60 months following surgery | — |
| Incidence of laboratory abnormalities | Up to 60 months following surgery | Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0) |
| Change in tumor-infiltrating CD8 T-cell density | Baseline to time of surgery | Defined as the change from baseline to the time of surgery |
Countries
United States
Contacts
STUDY_DIRECTORClinical Trial Management
Regeneron Pharmaceuticals
Outcome results
None listed